Doxepin Hydrochloride Tablet
NDC Package 51672-4247-2

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Doxepin Hydrochloride tablets is doxepin tablets is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance. This formulation utilizes a tablet delivery system. Marketed by Sun Pharmaceutical Industries, Inc., this product is identified by NDC 51672-4247 and is authorized under FDA application ANDA219058.

Identification & Billing

NDC Package Code
51672-4247-2
Package Description
30 TABLET in 1 BOTTLE
Product Code
51672-4247
11-Digit Billing Format
51672424702
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
30 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Doxepin Hydrochloride
Non-Proprietary Name
Doxepin Hydrochloride
Substance Name
Doxepin Hydrochloride
Dosage Form
Tablet - A solid dosage form containing medicinal substances with or without suitable diluents.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
DOXEPIN HYDROCHLORIDE 6 mg/1
Pharmacologic Class
Tricyclic Antidepressant - [EPC] (Established Pharmacologic Class)
Usage Information
Doxepin tablets is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance. The clinical trials performed in support of efficacy were up to 3 months in duration .

Regulatory & Marketing

Labeler Name
Sun Pharmaceutical Industries, Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA219058
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
08-07-2025
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 51672-4247-2 identifies a specific commercial package of 30 tablet in 1 bottle of Doxepin Hydrochloride, a human prescription drug labeled by Sun Pharmaceutical Industries, Inc.. This tablet is formulated for oral use and contains doxepin hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Sun Pharmaceutical Industries, Inc. on August 07, 2025. The current certification is valid through December 31, 2026.

How is this Sun Pharmaceutical Industries, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 51672424702. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
51672-4247-2
11-Digit CMS (5-4-2)
51672-4247-02

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.